Global Hypophosphatemia Treatment Market – Industry Trends and Forecast to 2030

Request for TOC TOC のリクエスト Speak to Analyst アナリストに相談する Buy Now今すぐ購入 Inquire Before Buying 事前に問い合わせる Free Sample Report 無料サンプルレポート

Global Hypophosphatemia Treatment Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 ページ
  • テーブル数: 220
  • 図の数: 60

Global Hypophosphatemia Treatment Market

Market Size in USD Billion

CAGR :  % Diagram

Diagram 予測期間
2023 –2030
Diagram 市場規模(基準年)
USD 25.70 Million
Diagram Market Size (Forecast Year)
USD 37.97 Million
Diagram CAGR
%
Diagram Major Markets Players
  • Kyowa Kirin Co
  • Smith+Nephew
  • Nestle
  • Pfizer
  • Koninklijke Philips

Global Hypophosphatemia Treatment Market, By Treatment (Medication, Surgical, Orthopaedic), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

Hypophosphatemia Treatment Market

Hypophosphatemia Treatment Market Analysis and Size

According to the statistics published in 2017 by the FDA, hypophosphatemia affected approximately 3,000 children and 12,000 adults in the U.S. The disorder is generally diagnosed in children with symptoms such as bent or bowed legs, severe dental and bone pain, and short stature. As per the National Center for Biotechnology Information (NCBI), in U.S. about 11-15% of the population are diagnosed with hyperphosphatemia each year where the majority of the population are suffering from diabetes and CVD. These set of people are at high risk of getting hypophosphatemia.

Data Bridge Market Research analyses a growth rate in the hypophosphatemia treatment market in the forecast period 2023-2030. The expected CAGR of hypophosphatemia treatment market is tend to be around 5% in the mentioned forecast period. The market was valued at USD 25.7 million in 2022, and it would grow upto USD 37.97 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Hypophosphatemia Treatment Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Treatment (Medication, Surgical, Orthopaedic), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Kyowa Kirin Co., Ltd (Japan), Smith+Nephew (U.K.), Nestle (Switzerland), Pfizer, Inc. (U.S.), Koninklijke Philips N.V. (Netherlands), ADM Animal Nutrition (U.S.), Ultragenyx Pharmaceutical (U.S.), Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. (China), Lilly (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Prospec-Tany Technogene Ltd (Israel)

Market Opportunities

  • Rise in elderly population

Market Definition

Hyperphosphatemia is a type of condition in which an abnormal amount of phosphate is present in the blood. The abnormal amount of phosphate is typically witnessed in the population with chronic kidney disease and cardiovascular diseases. In patients suffering from chronic kidney diseases, hyperphosphatemia is a primary cause of mortality and morbidity. The abnormal level of phosphates in hypophosphatemia causes numerous complications in the body including bone pain, bone fractures, appetite loss and confusion.

Global Hypophosphatemia Treatment Market Dynamics

Drivers

  • Increase R&D Activities

The increased R&D activities on hypophosphatemia causes the market to flourish. To overcome the burden of hyperphosphatemia, many treatment options have been studied and research has been carried out. Many phosphate-lowering hyperphosphatemia treatment approaches have been executed to manage and prevent hyperphosphatemia. This boosts the growth of the market.

  • Rising Healthcare Expenditure

The increasing research funding towards several rare diseases such as X-Linked Hypophosphatemia (XLH) and the high healthcare expenditure is also projected to increase the growth of the market during the forecast period. For instance, Genome Canada and the Canadian Institutes for Health Research entered into a partnership to study rare genetic diseases by using Next-Generation Sequencing (NGS) technology. Thus, this factor has impacted in a huge growth of the market.

Opportunities

  • Increase in Elderly Population

The market is estimated to witness a heavy growth rate in the forecast period driven by the factor of an aging population. The increasing demand in the market is the replication of increasing elderly population, as people aged over 60 years often develop low immunity conditions affecting the normal functioning. This boost the market growth.

Restraints/Challenges

  • Lack of skilled professionals

The lack of qualified healthcare professional unable to perform the treatments could reduce the growth of the hypophosphatemia treatment market during the forecast period.

  • Side-Effects of Hypophosphatemia Treatment

The adverse side-effects associated with the treatment process hinder the market growth. Effects such as hearing loss, infections and also some drugs can lead to autoimmune reactions.

This hypophosphatemia treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hypophosphatemia treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Hypophosphatemia Treatment Market Scope

The hypophosphatemia treatment market is segmented on the basis of treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

  • Medication
  • Surgical
  • Orthopaedic

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Hypophosphatemia Treatment Market Regional Analysis/Insights

The hypophosphatemia treatment market is analyzed and market size insights and trends are provided by treatment, distribution channel and end-user as referenced above.

The major countries covered in the hypophosphatemia treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for hypophosphatemia treatment market throughout the forecasted period due to high presence of key manufacturers of the product and, increasing research and development activities.

Asia-Pacific dominates the market due to increased new research and developments.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Hypophosphatemia Treatment Market Share Analysis

The hypophosphatemia treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hypophosphatemia treatment market.

Key players operating in the hypophosphatemia treatment market include:

  • Kyowa Kirin Co., Ltd (Japan
  • Smith+Nephew (U.K.)
  • Nestle (Switzerland)
  • Pfizer, Inc. (U.S.)
  • Koninklijke Philips N.V. (Netherlands)
  • ADM Animal Nutrition (U.S.)
  • Ultragenyx Pharmaceutical (U.S.)
  • Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. (China)
  • Lilly (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Prospec-Tany Technogene Ltd (Israel)


SKU-

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

  • インタラクティブなデータ分析ダッシュボード
  • 成長の可能性が高い機会のための企業分析ダッシュボード
  • カスタマイズとクエリのためのリサーチアナリストアクセス
  • インタラクティブなダッシュボードによる競合分析
  • 最新ニュース、更新情報、トレンド分析
  • 包括的な競合追跡のためのベンチマーク分析のパワーを活用
デモのリクエスト

調査方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。

Frequently Asked Questions

The market is segmented based on , By Treatment (Medication, Surgical, Orthopaedic), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030. .
The Global Hypophosphatemia Treatment Market size was valued at USD 25.70 USD Million in 2022.
The Global Hypophosphatemia Treatment Market is projected to grow at a CAGR of 5% during the forecast period of 2023 to 2030.
The major players operating in the market include Kyowa Kirin Co, Smith+Nephew, Nestle, Pfizer, Koninklijke Philips, ADM Animal Nutrition, Ultragenyx Pharmaceutical, Nanjing Jianyou Biochemical Pharmaceutical Co, Lilly, F. Hoffmann La Roche, Prospec, Tany Technogene Ltd.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.